The landscape of Type 1 Diabetes (T1D) management is undergoing a seismic shift. For decades, the primary benchmark for success was a single number delivered every three months: the HbA1c. Today, however, a more nuanced and real-time metric is taking center stage. "Time in Range" (TIR), powered by the rapid adoption of Continuous Glucose Monitoring (CGM) technology, is providing patients and clinicians with a high-definition view of metabolic health that was previously impossible to achieve.
n
As organizations like Breakthrough T1D (formerly JDRF) push the boundaries of research, the focus has moved beyond mere survival toward optimizing the quality of life and minimizing the "glucose roller coaster" that defines the daily existence of millions.
n
n
Main Facts: Defining the New Metrics of Success
n
Type 1 Diabetes is a chronic autoimmune condition where the pancreas produces little to no insulin. For those living with the disease, the margin for error is razor-thin. Blood sugar levels must be meticulously managed through a combination of insulin administration, carbohydrate counting, and constant monitoring. If levels climb too high (hyperglycemia), long-term complications like nerve damage and kidney failure loom; if they drop too low (hypoglycemia), the results can be immediate and life-threatening.
n
The Rise of the CGM
n
Historically, patients relied on finger-prick tests, which provide a "snapshot" of blood glucose at a single moment. While useful, these snapshots miss the "movie" of what happens between tests. Enter the Continuous Glucose Monitor (CGM). These wearable devices measure glucose levels in the interstitial fluid every one to five minutes. By providing up to 288 readings a day, CGMs allow for the calculation of Time in Range.
n
What is Time in Range?
n
Time in Range is defined as the percentage of time per day a person’s glucose levels remain within the target window of 70 to 180 milligrams per deciliter (mg/dL). While individual targets vary based on age and health status, the clinical consensus for most adults with T1D is to aim for a TIR of at least 70%.
n
This metric is revolutionary because it accounts for glucose variability. Two patients can have the same HbA1c—say 7.0%—but one may achieve it through stable readings, while the other experiences dangerous swings between extreme highs and lows. TIR identifies these swings, offering a more accurate reflection of a patient’s daily lived experience.
n
n
Chronology: From Snapshots to a Fully Closed Loop
n
The evolution of T1D management can be viewed as a progression toward increasing automation and precision. Understanding where we are requires looking at the technological milestones that brought us to the era of Time in Range.
n
The Era of Manual Monitoring (1970s–1990s)
n
Before the widespread availability of home glucose monitors, patients often relied on urine testing, which was notoriously inaccurate and lagged behind actual blood sugar levels. The introduction of portable glucose meters in the 1980s allowed for finger-prick testing, but management remained a manual, reactive process.
n
The CGM Revolution (2000s–2010s)
n
The first CGMs received FDA approval in the early 2000s. Initially, they were bulky and required frequent calibration with finger pricks. However, by the mid-2010s, "factory-calibrated" CGMs emerged, offering high accuracy without the need for supplemental blood draws. This era marked the birth of TIR as a viable clinical metric.
n
The Age of Automated Insulin Delivery (2017–Present)
n
The current frontier is the Automated Insulin Delivery (AID) system, often called the "artificial pancreas." These systems link a CGM with an insulin pump, using sophisticated algorithms to automatically increase or decrease insulin delivery in real-time.
n
Breakthrough T1D has been a primary driver of this innovation. Current AID systems have significantly improved TIR by catching "lows" before they happen and mitigating "highs" overnight. However, we are still in an "interim" phase where patients must manually announce meals to the system. The next chronological step, currently in clinical trials, is the "fully closed-loop" system, which will require no manual input for meals or exercise.
n
n
Supporting Data: The Statistics of Stability
n
To understand why TIR is gaining such traction, one must look at the data-driven standards established by the global diabetes community. According to current standards of care, the goals for a typical adult with T1D are structured to prioritize safety and long-term health:
n
- n
- Time in Range (70–180 mg/dL): Target > 70% (approx. 17 hours/day).
- Time Above Range (> 180 mg/dL): Target < 25% (approx. 6 hours/day).
- Time Below Range (< 70 mg/dL): Target < 4% (approx. 1 hour/day).
- Urgent Lows (< 54 mg/dL): Target < 1% (approx. 15 minutes/day).
n
n
n
n
n
TIR vs. HbA1c: A Comparative Analysis
While HbA1c measures the percentage of hemoglobin coated with sugar over 2–3 months, it is a weighted average. It cannot distinguish between a patient who is "flat-lining" at 150 mg/dL and a patient who spends half their day at 300 mg/dL and the other half at 50 mg/dL.
Supporting research indicates that spending more time in range is directly associated with a lower risk of microvascular complications, such as retinopathy (eye disease) and nephropathy (kidney disease). This makes TIR not just a metric of convenience, but a critical predictor of longevity.
The Emergence of "Time in Tight Range" (TITR)
As technology improves, researchers are looking toward an even more ambitious metric: Time in Tight Range (TITR), or "normal glycemia." This narrows the window to 70–140 mg/dL.
- The Benchmark: People without diabetes spend approximately 96% of their time in this tight range.
- The Data: Recent clinical trials, including the Breakthrough T1D-funded ADJUST-T1D trial, have shown that non-insulin therapies like GLP-1 receptor agonists (e.g., semaglutide) can significantly increase TITR in T1D patients who are overweight or obese, providing a glimpse into a future where "normal" glucose levels are achievable for the T1D community.
Official Responses: Insights from the Experts
Leadership at Breakthrough T1D emphasizes that TIR is about more than just numbers; it is about the psychological and physical burden of the disease.
Dr. Brynn E. Marks, M.D., MSHPEd, Senior Director of Medical Affairs at Breakthrough T1D, highlights the empowerment that comes with real-time data. "Time in range helps people with T1D better understand glucose patterns that are not captured by HbA1c," she explains. "Reviewing and acting on TIR data identified by CGM can empower people to manage their T1D and to avoid the roller coasters of managing high and low blood glucose that negatively impact quality of life."
Dr. Marks points out that the ability to make frequent adjustments between doctor visits is a game-changer. Rather than waiting three months for an HbA1c result to realize a plan isn’t working, a patient can look at a 14-day CGM trend and pivot immediately.
Dr. Jonathan Rosen, Ph.D., Director of Research at Breakthrough T1D, sees TIR as a catalyst for systemic change in how the medical community evaluates new treatments. "In the future, I think we will see greater use of TIR in T1D management as adoption of CGM continues to increase," Rosen states. "These data might not only support CGM use in clinical decision-making but may also impact the way new therapies are evaluated."
Rosen notes that while TIR is widely accepted for evaluating hardware (like AID systems), the regulatory world is still catching up in using it to evaluate new drug therapies. He believes TIR will eventually become the standard by which all diabetes interventions—biological or technological—are judged.
Implications: The Future of Care and Research
The shift toward Time in Range carries profound implications for the future of healthcare policy, drug development, and patient equity.
1. Clinical Trial Design
TIR is increasingly used as a primary endpoint in clinical trials. This allows researchers to see the immediate impact of a drug or device on a patient’s daily life. For instance, the ADJUST-T1D trial demonstrated that semaglutide improved both TIR and TITR over 26 weeks. This evidence is crucial for expanding the "toolbox" of T1D treatments beyond just insulin.
2. The Move Toward Non-Insulin Adjuncts
The realization that insulin alone is often insufficient to reach TIR goals has spurred research into non-insulin therapies. Breakthrough T1D is currently funding studies on drugs that address insulin resistance, weight management, and hypoglycemia unawareness. The goal is a personalized cocktail of therapies that makes staying "in range" feel effortless rather than a full-time job.
3. Reducing the "Undo Burden"
Perhaps the most significant implication is the focus on "burden." While "Time in Tight Range" (70-140 mg/dL) is the ultimate physiological goal, the medical community is wary of the mental health toll of chasing such a narrow window. Future technologies must achieve these targets automatically. The goal of the "Improving Lives Program" is to ensure that while researchers hunt for a biological cure, the technology available now reduces the cognitive load of the disease.
4. Advocacy and Access
As TIR becomes the gold standard, the implication for advocacy is clear: CGM access is no longer a luxury; it is a medical necessity. Breakthrough T1D and other organizations are working to clear approval and coverage pathways to ensure that socio-economic status does not dictate whether a patient can access the data needed to stay in range.
Conclusion
The transition from the static HbA1c to the dynamic Time in Range represents a coming-of-age for diabetes technology. By providing a comprehensive picture of a person’s glucose trends, TIR offers a roadmap for personalized care that prioritizes both long-term health and daily well-being. As we move toward fully closed-loop systems and integrated drug therapies, the "roller coaster" of T1D may finally be replaced by a steady, manageable path, allowing those with the condition to live lives defined by their potential rather than their blood sugar.
